In 1996 was created EFung Capital, which is appeared as VC. The company was established in Asia in China. The main department of described VC is located in the Shenzhen.
Speaking about the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. This EFung Capital works on 14 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2001.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the EFung Capital, startups are often financed by InterWest Partners, Shenzhen Capital Group, Quan Capital. The meaningful sponsors for the fund in investment in the same round are Panacea Venture, YuanMing Capital, Viventures. In the next rounds fund is usually obtained by YuanMing Capital, State Development & Investment Corporation (SDIC), RMB Funds.
We also calculated 4 valuable employees in our database.
The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Centrexion, Elicio Therapeutics, Resverlogix.
Funds with similar focus
|APICIL Group||Caluire-et-cuire, France, Rhone-Alpes|
|Bluebird Bio||Cambridge, Massachusetts, United States|
|BUYOVERCHAT TECHNOLOGIES LIMITED||Lagos, Lagos, Nigeria|
|GCC Investments LLC||Massachusetts, United States, Wellesley|
|Gongyinglian Chanye Fazhan Jijin||China, Henan, Henan|
|Guangdong Hengjian Venture Capital||China, Guangdong Province, Huizhou|
|Hightower||New York, New York, United States|
|QD Ventures||Castel, Guernsey, Guernsey|
|S5 Partners||Japan, Tokyo|
|SEA Ventures||Pennsylvania, Pittsburgh, United States|
|Seewo College||China, Guangdong, Guangzhou|
|Shanghai Yongquan Yixin Investment Development Center||China, Shanghai|
|Sunflower Development Group||-|
|The Yoshida Group||Oregon, Portland, United States|
|WaterEquity||Kansas City, Missouri, United States|
|Wishcompany||Seoul, Seoul-t'ukpyolsi, South Korea|
|Zhejiang Merit Interactive Network Technology||China, Hangzhou, Zhejiang|
|$77M||17 Jan 2023||Xuanwu District, Jiangsu, China|
|$57M||05 Jan 2023||Guangzhou, Guangdong, China|
|03 Jan 2023||Shenzhen, Guangdong, China|
|29 Dec 2022||Yuexiu District, Guangdong Province, China|
|27 May 2022||Chengdu, Sichuan, China|
|$15M||29 Mar 2022||Hangzhou, Zhejiang, China|
|21 Feb 2022||Shenzhen, Guangdong, China|
West Lake Omi
|13 Jan 2022||Otsu, Shiga Prefecture, Japan|
Atom Bioscience & Pharmaceutical
|$45M||05 Jan 2022||Zhenjiang, Guangdong Province, China|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.